Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Merck & Co (NY:MRK)

86.32 UNCHANGED
Streaming Delayed Price Updated: 7:00 PM EDT, Oct 20, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Merck & Co

< Previous 1 2
...
10 11 12 13 14 15 16 17 18
...
99 100 Next >
These S&P500 stocks are moving in today's session
Curious about the top performers within the S&P500 index one hour before the close of the markets on Friday? Dive into the list of today's session's top gainers and losers for a comprehensive... 
Via Chartmill
Merck Stays Confident On M&A Despite Market Uncertainty: Analyst
Merck projects $200 million in tariff costs, boosts U.S. manufacturing plans, and continues M&A efforts amid external pressures and shifting market dynamics. 
Via Benzinga
Topics World Trade
What's Going On With Summit Therapeutics Stock On Friday?
Summit Therapeutics' partner Akeso received FDA approval for penpulimab-kcqx in NPC, while ivonescimab showed strong data in lung cancer trials. 
Via Benzinga
Market Monitor April 25 ( Texas Instruments, Nvidia & Amazon UP, IBM, PepsiCo & Comcast DOWN)
Wall Street Rallies Again: Tech Leads the Charge, Alphabet Shines After-Hours 
Via Chartmill
Earnings Scheduled For April 24, 2025
 
Via Benzinga
Merck (MRK) Q1 2025 Earnings Call Transcript
Via The Motley Fool
Topics Earnings World Trade
Halozyme Sues Merck Over Subcutaneous Keytruda Formulation, Seeks Injunctive Relief
Halozyme said that it believes the subcutaneous formulation of Merck's cancer medicine Keytruda infringes multiple patents that Halozyme filed beginning in 2011 to protect its groundbreaking MDASE... 
Via Stocktwits
Topics Intellectual Property Lawsuit
Merck's Q1 Earnings Beat Wall Street, Adjusts 2025 Profit Outlook As Tariffs May Result In Incremental Cost Of $200 Million
Merck posted Q1 adjusted EPS of $2.22 and revenue of $15.53 billion, beating estimates while revising full-year guidance amid tariff-related cost pressure. 
Via Benzinga
Topics Earnings
Merck & Co. Reports Better Than Expected Results For First-Quarter 2025
Merck's Q1 2025 results show a slight decrease in total sales but highlight growth in key segments. 
Via Talk Markets
Topics Stocks / Equities
Durable Goods Orders Jump 9.2% In March, But One Category Tells The Real Story
US durable goods orders surged in March, but with a mixed picture. Transportation equipment led the gain, while other sectors showed minimal growth or decline. 
Via Benzinga
Wall Street Rally Extends Into Third Day: What's Driving Markets Thursday?
U.S. equities are pushing higher for a third straight session, eyeing the longest winning streak since the Trump tariff announcement on April 2, as optimism over corporate earnings and easing trade... 
Via Benzinga
Topics Government World Trade
Merck Reports Strong Q1 Earnings But Downgrades Full-Year Guidance: Retail Sentiment Brightens
Merck estimates that the impact of tariffs implemented to date will result in incremental costs of approximately $200 million. 
Via Stocktwits
Topics Government World Trade
Merck’s (NYSE:MRK) Q1 Sales Beat Estimates
Global pharmaceutical company Merck (NYSE:MRK) beat Wall Street’s revenue expectations in Q1 CY2025, but sales fell by 1.6% year on year to $15.53 billion. The company expects the full year’s revenue... 
Via StockStory
Topics Artificial Intelligence Earnings Intellectual Property
Gardasil Sales Decline — Again. Can Dow Jones Stock Merck Take The Hit?
This is the third quarter of accelerating sales declines amid slow demand in China for Gardasil vaccines. 
Via Investor's Business Daily
Topics Earnings Government Stocks
Merck Announces First-Quarter 2025 Financial Results
From Merck & Co., Inc.
Via Business Wire
Why Is Summit Therapeutics Stock Soaring On Wednesday?
Summit and Akeso report Phase 3 success as ivonescimab shows PFS gains in NSCLC trial, with new studies and collaborations underway. 
Via Benzinga
Merck Stock Slumps Ahead Of Q1 Earnings: Can Bulls Find Relief In Buying Pressure?
Merck & Co reports Q1 earnings on Thursday with EPS of $2.14 and revenue of $15.33B expected. Despite a 38.04% drop in stock over past year, analysts see ~30% upside potential. 
Via Benzinga
BioNTech Surges On Summit's Coattails. But Can They Take On Merck?
BioNTech is on the rise after Summit Therapeutics unveiled promising results for its PD-1- and VEGF-blocking drug. 
Via Investor's Business Daily
Merck (MRK) Reports Q1: Everything You Need To Know Ahead Of Earnings
Global pharmaceutical company Merck (NYSE:MRK) will be reporting results tomorrow before market hours. Here’s what to expect. 
Via StockStory
Gilead Cancer Drug Combined With Merck's Drug Effective In Difficult To Treat Type Of Breast Cancer
Gilead's Trodelvy and Merck's Keytruda improved progression-free survival in PD-L1+ metastatic TNBC in a Phase 3 trial with no new safety concerns. 
Via Benzinga
Gilead Announces Positive Results From Trodelvy-Keytruda Combo Study For Breast Cancer: But Retail’s Unmoved
Triple-negative breast cancer accounts for approximately 15% of all breast cancers and has a higher chance of recurrence. 
Via Stocktwits
Wall Street's Most Accurate Analysts Give Their Take On 3 Health Care Stocks Delivering High-Dividend Yields
 
Via Benzinga
Why Merck, Black Hills, And Virtus Investment Partners Are Winners For Passive Income
 
Via Benzinga
ETF Shake-Up: UNH's Meltdown Meets LLY's Moonshot
Healthcare sector sees volatility due to UnitedHealth's earnings disappointment, but ETFs like XLV, IHE, and XPH still show resilience and pockets of strength. 
Via Benzinga
Topics ETFs
Where Will Eli Lilly Be in 5 Years?
Via The Motley Fool
MERCK ALERT: Bragar Eagel & Squire, P.C. is Investigating Merck & Co., Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
Assessing Merck & Co: Insights From 9 Financial Analysts
 
Via Benzinga
Pharmaceuticals Stocks Q4 In Review: Jazz Pharmaceuticals (NASDAQ:JAZZ) Vs Peers
Earnings results often indicate what direction a company will take in the months ahead. With Q4 behind us, let’s have a look at Jazz Pharmaceuticals (NASDAQ:JAZZ) and its peers. 
Via StockStory
Topics Artificial Intelligence Intellectual Property
Price Over Earnings Overview: Merck & Co
 
Via Benzinga
Merck Signs Nearly $500 Million Licensing Deal With Austria-Based Cyprumed For Tablet-Based Peptide Delivery
Merck signs deal with Austria's Cyprumed to develop oral peptide therapies, potentially paying up to $493 million for access to delivery technology. 
Via Benzinga
< Previous 1 2
...
10 11 12 13 14 15 16 17 18
...
99 100 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.